boothcheck doesn't label VRTX overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, VRTX is priced for growth of +21.4%, and an operating margin near 10.2% versus the 34.8% it earns today. The price is justified by relative-multiple; asset-based/earnings-power land below the price. The more the price assumes beyond what VERTEX PHARMACEUTICALS INC / MA has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.
Derived from VERTEX PHARMACEUTICALS INC / MA's SEC EDGAR filings via a reverse-DCF inversion. Last analyzed July 3, 2026.
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.